Article Text

PDF

Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project)
  1. A Kastbom,
  2. G Strandberg,
  3. A Lindroos,
  4. T Skogh
  1. Division of Rheumatology/AIR, Department of Molecular and Clinical Medicine, Faculty of Health Sciences, Linköping University Hospital, Linköping, Sweden
  1. Correspondence to:
    Professor T Skogh
    Division of Rheumatology/AIR, Department of Molecular and Clinical Medicine, Faculty of Health Sciences, Linköping University Hospital, SE-581 85 Linköping, Sweden; thomas.skoghlio.se

Abstract

Objectives: To evaluate the diagnostic sensitivity of antibodies to cyclic citrullinated peptide (CCP) in recent onset rheumatoid arthritis (RA) at diagnosis and 3 years later, and to evaluate anti-CCP antibody as a predictor of the disease course during 3 years.

Methods: 242 patients with recent onset (⩽1 year) RA were followed up regularly during 3 years after inclusion in the Swedish multicentre study “TIRA” 1996–98. Anti-CCP antibodies were analysed by an enzyme immunoassay (EIA). Rheumatoid factors (RFs) were analysed by latex agglutination and two isotype-specific (IgM and IgA) EIAs. Disease activity was assessed by plasma CRP, ESR, 28 joint disease activity score, and the physician’s global assessment of disease activity. Functional ability was evaluated by the Health Assessment Questionnaire.

Results: Overall, the diagnostic sensitivity of anti-CCP antibodies was 64% and the proportion of positive tests increased with the number of fulfilled classification criteria according to the American College of Rheumatology. The anti-CCP antibody results correlated with RF, but were better than RF as predictor of a more aggressive disease course. After 3 years 5/97 patients had changed anti-CCP status: 2 from negative to positive and 3 from positive to negative. The mean level of anti-CCP antibodies declined by 131 U/ml during the 3 year follow up (95% CI 34 to 228 U/ml).

Conclusion: The anti-CCP antibody assay has a similar diagnostic sensitivity to that of RF in early RA, but is better as a predictor of the disease course over 3 years. Although the mean serum level declines, anti-CCP antibody positivity remains essentially unaltered 3 years after diagnosis and start of antirheumatic treatment.

  • ACR, American College of Rheumatology
  • CCP, cyclic citrullinated peptide
  • COMP, cartilage oligomeric protein
  • CRP, C reactive protein
  • DAS28, 28 joint count disease activity score
  • DMARD, disease modifying antirheumatic drug
  • EIA, enzyme immunoassay
  • ESR, erythrocyte sedimentation rate
  • HAQ, Health Assessment Questionnaire
  • PGA, physician’s global assessment
  • RA, rheumatoid arthritis
  • RF, rheumatoid factor
  • anti-CCP antibody
  • rheumatoid factor
  • early rheumatoid arthritis
  • inflammation
  • disease course

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.